Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

Abstract Background Advances in multi-modality treatment of locally advanced rectal cancer (LARC) have resulted in low local recurrence rates, but around 30% of patients will still die from distant metastatic disease. In parallel, there is increasing recognition that with radiotherapy and systemic t...

Full description

Bibliographic Details
Main Authors: Catherine R. Hanna, Sean M. O’Cathail, Janet S. Graham, Mark Saunders, Leslie Samuel, Mark Harrison, Lynsey Devlin, Joanne Edwards, Daniel R. Gaya, Caroline A. Kelly, Liz-Anne Lewsley, Noori Maka, Paula Morrison, Louise Dinnett, Susan Dillon, Jacqueline Gourlay, Jonathan J. Platt, Fiona Thomson, Richard A. Adams, Campbell S. D. Roxburgh
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Radiation Oncology
Subjects:
Rectal
Neoplasm
Chemotherapy
Radiotherapy
Immune-oncology
Immunotherapy
Online Access:https://doi.org/10.1186/s13014-021-01888-1

Internet

https://doi.org/10.1186/s13014-021-01888-1

Similar Items